The small molecule YK-4-279 was originally identified by surface plasmon resonance (SPR) and developed for Ewing’s sarcoma to block EWS-FLI1 binding to DHX9/RNA helicase A (RHA), an important cofactor for its oncogenic activity [145]. Here, EWSR1 is linked to Ewing sarcoma.